1. Home
  2. STKS vs SGMT Comparison

STKS vs SGMT Comparison

Compare STKS & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The ONE Group Hospitality Inc.

STKS

The ONE Group Hospitality Inc.

HOLD

Current Price

$1.82

Market Cap

58.4M

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$7.16

Market Cap

169.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
STKS
SGMT
Founded
2004
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
58.4M
169.4M
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
STKS
SGMT
Price
$1.82
$7.16
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
8
Target Price
$4.70
$26.13
AVG Volume (30 Days)
12.1K
862.2K
Earning Date
05-04-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$805,722,000.00
$2,000,000.00
Revenue This Year
$7.47
N/A
Revenue Next Year
$8.12
N/A
P/E Ratio
N/A
N/A
Revenue Growth
19.66
N/A
52 Week Low
$1.65
$4.50
52 Week High
$3.38
$10.06

Technical Indicators

Market Signals
Indicator
STKS
SGMT
Relative Strength Index (RSI) 45.24 47.15
Support Level $1.69 $6.95
Resistance Level $2.03 $7.39
Average True Range (ATR) 0.09 0.44
MACD -0.01 -0.05
Stochastic Oscillator 22.65 18.55

Price Performance

Historical Comparison
STKS
SGMT

About STKS The ONE Group Hospitality Inc.

The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through three segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: